Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dicyclomine
Drug ID BADD_D00659
Description Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable.[L7982] Dicyclomine was granted FDA approval on 11 May 1950.[L7967]
Indications and Usage Dicyclomine is indicated for the treatment of functional bowel disorder and irritable bowel syndrome.[L7967]
Marketing Status approved
ATC Code A03AA07
DrugBank ID DB00804
KEGG ID D07820
MeSH ID D004025
PubChem ID 3042
TTD Drug ID D07XJM
NDC Product Code Not Available
UNII 4KV4X8IF6V
Synonyms Dicyclomine | Dicycloverin | Dicyclomine Hydrochloride | Hydrochloride, Dicyclomine | Merbentyl | Bentylol | Spascol | Di-Spaz | Di Spaz | Dibent | Diclomin | Lomine | OR-Tyl | OR Tyl | Bentyl | Di-Cyclonex | Di Cyclonex
Chemical Information
Molecular Formula C19H35NO2
CAS Registry Number 77-19-0
SMILES CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.000489%Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.0020.000663%
Abdominal pain upper07.01.05.0030.000532%
Accommodation disorder06.02.04.001--Not Available
Ageusia17.02.07.001; 07.14.03.003--Not Available
Agitation19.06.02.001; 17.02.05.0120.000279%
Amnesia17.03.02.001; 19.20.01.0010.000131%
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Anhedonia19.15.02.0070.000087%Not Available
Anxiety19.06.02.0020.000733%
Apnoea22.02.01.001--
Asphyxia22.02.02.001; 12.01.08.011--Not Available
Asthenia08.01.01.0010.000131%Not Available
Benign prostatic hyperplasia21.04.02.001--Not Available
Cervicobrachial syndrome15.01.04.002; 17.10.02.001--Not Available
Cholecystitis09.03.01.0010.000131%
Cholecystitis chronic09.03.01.0040.000087%Not Available
Condition aggravated08.01.03.0040.000131%Not Available
Confusional state19.13.01.001; 17.02.03.0050.000131%
Constipation07.02.02.0010.000174%
Crohn's disease10.02.01.005; 07.08.01.0150.000087%Not Available
Cycloplegia17.17.02.003; 06.05.03.002--Not Available
Delirium19.13.02.001--
Delusion19.10.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Diarrhoea07.02.01.0010.000768%
Diplopia17.17.01.005; 06.02.06.002--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages